CSE’s Barrington Miller recently chatted with Iris Bincovich, the CEO of InnoCan Pharma Corporation (CSE:INNO) to discuss their recent patent application. In this chat, Iris shares how her team is designing CBD-loaded exosomes for targeting Coronavirus infected lung cells (2:15), how to improve CBD delivery through an injectable solution (7:53), and her prospects concerning a second wave of the virus later in the year (9:48).
The CSE was happy to join InnoCan Pharma Corporation (CSE:INNO) for a Market Open from a special international location, with members of the InnoCan team ringing the bell on a beach in Tel Aviv, Israel.
InnoCan Pharma Corporation is an Israel-based speciality pharmaceutical company that uses cannabis products to target health issues. The company specializes in the research, development, marketing, and sales of InnoCan-branded over the counter pharmaceutical and non-pharmaceutical products. InnoCan believes that by merging pharma, science, and the therapeutic benefits of cannabinoids, it is possible to create a truly effective over the counter topical treatments product line.
“We are proud to open the market from the beautiful beach of Tel Aviv,” said InnoCan Pharma Corporation CEO Iris Bincovich.
“We are honoured and happy to be the first Israeli cannabis company that has filed in the CSE and concluded a successful round of fundraising,” remarked Innocan Pharma Corporation Executive Chairman Ron Mayron. “InnoCan is a unique value proposition company which can offer a wide range of products and a wide range of system deliveries, and we hope we’ll be one of the leading companies in this area in Canada.”
Joining Bincovich and Mayron at this momentous Market Open were other key members of the InnoCan Pharma Corporation team, as well as Mark Francis, Capital Markets Consultant and Senior Advisor at the CSE.
For more details about the CSE Media Centre, including information on upcoming Market Opens, please visit the CSE website, or follow us on social media.